![Richard Stuart Godfrey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Richard Stuart Godfrey
Président chez
Uni Targeting Research AS
Profil
Richard Stuart Godfrey is currently the Chairman of Uni Targeting Research AS and a Member of the Royal Pharmaceutical Society of Great Britain.
He previously served as the Chief Executive Officer of Aenova Holding GmbH, BerGenBio ASA, and IRLAB Therapeutics AB. He also held positions as the Managing Director of DCC Healthcare Ltd., Director of ArcticZymes Technologies ASA and Balter Medical AS, Sales Manager at Reckitt Benckiser Group Plc, and Chief Operating Officer of Lifearc.
Additionally, he was a Partner at Sarsia Venture Management AS and worked as a Principal at both Catalent Pharma Solutions Ltd. and Eli Lilly Norge AS.
Mr. Godfrey holds an MBA from the University of Bath and an undergraduate degree from the University of Liverpool.
Postes actifs de Richard Stuart Godfrey
| Sociétés | Poste | Début |
|---|---|---|
Uni Targeting Research AS
 Uni Targeting Research AS BiotechnologyHealth Technology Provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures | Président | - |
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services Provides expertise and support to its member pharmacists | Corporate Officer/Principal | - |
Anciens postes connus de Richard Stuart Godfrey
| Sociétés | Poste | Fin |
|---|---|---|
| IRLAB THERAPEUTICS AB | Directeur Général | 20/02/2023 |
| ONCOINVENT ASA | Directeur Général | 22/08/2021 |
Sarsia Venture Management AS
 Sarsia Venture Management AS Investment ManagersFinance SVM is an active, growth oriented investment manager. Their financing strategy concentrates on divestment and capital return. The fund has a life sciences and biotechnology sector focus, specifically investing in areas such as diagnostics, medical technology and nutraceuticals. The fund takes minority stakes generally ranging from 15% to 40%. They typically make a total investment from NOK 8 million to NOK 40 million from initial engagement until divestment. Follow-on investments are assessed through milestone-based criteria. To facilitate growth and development, they also pursue strategic alliance and consolidation opportunities. Their exit horizon is three to five years. SVM works closely and takes an active role with their portfolio firms. The fund also has a robust industrial and academic advisory board. | Private Equity Investor | 31/12/2015 |
Lifearc
 Lifearc Miscellaneous Commercial ServicesCommercial Services Operates as a life science medical research charity company | Directeur des opérations | - |
| ARCTICZYMES TECHNOLOGIES ASA | Directeur/Membre du Conseil | - |
Formation de Richard Stuart Godfrey
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
71
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Reckitt Benckiser Group Plc
 Reckitt Benckiser Group Plc Household/Personal CareConsumer Non-Durables Manufactures and markets household cleaning, health and nutrition products | Consumer Non-Durables |
University of Bath
 University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services Provides expertise and support to its member pharmacists | Commercial Services |
The University of Liverpool
 The University of Liverpool Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DCC Healthcare Ltd.
 DCC Healthcare Ltd. Medical/Nursing ServicesHealth Services Provides healthcare and technology solutions | Health Services |
ArcticZymes Technologies ASA
 ArcticZymes Technologies ASA Medical SpecialtiesHealth Technology Develops and manufactures immune modulating compounds | Health Technology |
Lifearc
Lifearc Miscellaneous Commercial ServicesCommercial Services Operates as a life science medical research charity company | Commercial Services |
Sarsia Venture Management AS
Sarsia Venture Management AS Investment ManagersFinance SVM is an active, growth oriented investment manager. Their financing strategy concentrates on divestment and capital return. The fund has a life sciences and biotechnology sector focus, specifically investing in areas such as diagnostics, medical technology and nutraceuticals. The fund takes minority stakes generally ranging from 15% to 40%. They typically make a total investment from NOK 8 million to NOK 40 million from initial engagement until divestment. Follow-on investments are assessed through milestone-based criteria. To facilitate growth and development, they also pursue strategic alliance and consolidation opportunities. Their exit horizon is three to five years. SVM works closely and takes an active role with their portfolio firms. The fund also has a robust industrial and academic advisory board. | Finance |
Aenova Holding GmbH
 Aenova Holding GmbH Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical for healthcare industries | Health Technology |
Uni Targeting Research AS
Uni Targeting Research AS BiotechnologyHealth Technology Provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures | Health Technology |
Catalent Pharma Solutions Ltd.
 Catalent Pharma Solutions Ltd. Pharmaceuticals: MajorHealth Technology Develops and markets drug delivery systems | Health Technology |
Eli Lilly Norge AS
 Eli Lilly Norge AS Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
Balter Medical AS
 Balter Medical AS Medical SpecialtiesHealth Technology Develops and commercializes devices to aid tissue diagnostics | Health Technology |
IRLAB Therapeutics AB
 IRLAB Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for neurological diseases | Health Technology |
